Passage Bio, Inc. (PASG) Q3 2022 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Passage Bio, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.029 -- 00:00:03.752 Thank you for holding. Good morning and welcome to the passage of our third quarter 2022 00:00:03.752 -- 00:00:06.074 financial and operating results conference call. 00:00:06.074 -- 00:00:08.636 At this time, all participants are in a listen-only mode. 00:00:08.636 -- 00:00:11.618 Following the formal remarks, we will open the call up for your questions. 00:00:11.618 -- 00:00:14.740 Please be advised this call is being recorded at the company's request. 00:00:14.740 -- 00:00:18.003 Now I'd like to turn the call over to Stuart Henderson, Vice President of Corporate Development 00:00:18.003 -- 00:00:18.843 and Investor Relations. 00:00:18.843 -- 00:00:21.364 Stuart, please proceed. 00:00:25.108 -- 00:00:26.482 Thank you, Operator. 00:00:26.482 -- 00:00:31.105 This morning, we issued a press release that outlines the topics we plan to discuss today. 00:00:31.105 -- 00:00:35.328 This release is available on the Passage Bio website under the Press Releases and Statements 00:00:35.328 -- 00:00:40.411 section of Investors in News. On today's call, our recently appointed Chief 00:00:40.411 -- 00:00:45.534 Executive Officer, Will Chu, will review our third quarter 2022 and recent 00:00:45.534 -- 00:00:50.097 business highlights. Mark Foreman, our Chief Medical Officer, will review our clinical 00:00:50.097 -- 00:00:54.359 programs. And Simona King, our Chief Financial Officer, will review our third quarter 00:00:54.359 -- 00:00:57.711 2022 financial results. 00:00:57.711 -- 00:01:02.013 Before we begin, please note that today's call may include a number of forward-looking 00:01:02.013 -- 00:01:07.196 statements, including but not limited to comments on our expectations about timing 00:01:07.196 -- 00:01:11.818 and execution of anticipated ...